Home

helps physicians and healthcare professionals

Erectile Dysfunction

helps physicians and healthcare professionals

Doctor123.org

helps physicians and healthcare professionals

Acrodermatitis Continua


BASICS


  • Acropustular eruption with a predilection for distal digits characterized by sterile pustules; early nail involvement; and a persistent, relapsing course
  • Classified as a noninfectious neutrophilic dermatosis and variant of pustular psoriasis
  • Synonym(s): acrodermatitis continua of Hallopeau; acrodermatitis perstans; dermatitis repens; pustular acrodermatitis

DESCRIPTION


  • Acute-phase morphology
    • Around and under the nail(s) are multiple, sterile, erythematous-based, painful pustules that coalesce to form polycyclic "lakes of pus,"Ł which subsequently rupture and crust.
  • Chronic sequelae occur secondary to recurrent eruptions.
    • Nail changes: paronychia, onychodystrophy, onycholysis, onychomadesis, and anonychia
    • Scaling of the nail bed and periungual skin
    • Sclerosis or atrophy of soft tissue adjacent and deep to nail bed
    • Osteolysis of underlying bone, particularly distal phalanges
  • Distribution
    • Usually affects one to two digits, most frequently the first digits of the hands but may involve all fingers and toes
    • Most often distal but may rarely spread proximally to involve feet, ankles, hands, and forearms
    • Predilection for dorsal surfaces of hands and feet with sparing of central palmar and plantar regions
    • Isolated proximal psoriatic plaques are rare.

EPIDEMIOLOGY


  • Exceedingly rare: Only case studies and series are available.
  • Female predominance
  • Predominantly in adults but also seen in children: observed in 4.7% cases of infantile psoriasis in one series

ETIOLOGY AND PATHOPHYSIOLOGY


  • Immune dysregulation: Acute-phase reactants such as IL-1 and IL-36 likely play a role in pathogenesis (1,2).
  • In some instances, digital trauma or infection may be an inciting event.

Genetics
  • Reported associations with mutations in the IL36RN gene, which codes for the IL36 receptor antagonist, and is a cause of familial generalized pustular psoriasis (2,3).
  • No observed relationship with plaque psoriasis-associated alleles HLA-B13, B17, or BW37

RISK FACTORS


  • History of psoriasis, particularly pustular variant
  • Digital trauma
  • Local infection
  • Smoking may contribute to exacerbations.

COMMONLY ASSOCIATED CONDITIONS


  • Palmoplantar pustular psoriasis (PPP)
  • Generalized pustular psoriasis (GPP) (4)
  • Psoriatic arthritis (5,6)

DIAGNOSIS


  • Defined by clinical evolution and histopathologic features
  • Frequently missed, often a diagnosis of exclusion

HISTORY


  • Onset, including any triggering event
  • Duration of eruption, previous episodes
  • Local trauma or infection
  • Impairment in manual dexterity or ambulation
  • Localized symptoms: pain, pruritus, arthritis
  • Systemic symptoms: fever, malaise, weight loss
  • History of other immune disorder such as psoriasis, arthritis, or celiac disease
  • Smoking history

PHYSICAL EXAM


  • Examine all skin surfaces, nails, scalp, and mucous membranes.
  • Examine and palpate joints, evaluating for swelling, erythema, or effusion.
  • Palpate axillary, epitrochlear, and inguinal lymph nodes to assess for lymphadenopathy.
  • Observe and evaluate gait and manual dexterity.
  • Measure vital signs.

DIFFERENTIAL DIAGNOSIS


  • Bacterial infection, especially staphylococcal
  • Herpetic whitlow
  • Cutaneous candidiasis
  • Allergic contact dermatitis
  • Dyshidrotic eczema
  • Parakeratosis pustulosa (in children)
  • Pemphigus vulgaris
  • Squamous cell carcinoma, particularly in advanced disease

DIAGNOSTIC TESTS & INTERPRETATION


  • Cultures are sterile, unless secondary infection is present.
  • There are no characteristic serologic findings; however, acute systemic inflammation during flares may result in
    • Increased neutrophil count
    • Increased C-reactive protein

Initial Tests (lab, imaging)
  • The following should be performed on fluid obtained from pustules:
    • Gram stain smear
    • Potassium hydroxide preparation
    • In vitro culture
  • X-rays of hands and feet may show acro-osteolysis, especially in long-standing disease. Ankle osteolysis may also be observed, and is usually unilateral.

Follow-Up Tests & Special Considerations
Additional laboratory tests may be necessary to monitor for side effects of treatment. á
Diagnostic Procedures/Other
Full-thickness cutaneous punch biopsy of an active pustule may establish diagnosis and should be performed (7,8). á
Test Interpretation
  • Nail bed epithelium and adjacent epidermis
    • Compact hyperkeratosis with parakeratosis with or without neutrophils
    • Focal, subcorneal neutrophilic aggregates
    • Spongiform pustules of Kogoj (leukocyte aggregates between epidermal cells, associated with spongiosis)
    • Psoriasiform epidermal hyperplasia
    • Hemorrhagic foci displaying erythrocytes and hemosiderin
  • Dermis
    • Superficial perivascular inflammatory infiltrate composed of lymphocytes, histiocytes, and neutrophils
    • Tortuous, dilated vessels displaying erythrocyte extravasation
    • Edema of papillary dermis

TREATMENT


  • Due to the rarity of this disease, only expert opinion and case reports are available to guide treatment recommendations.
  • Notoriously refractory to treatment, including topical and systemic agents used successfully in psoriasis
  • The agents listed below may be more effective when used in combination than as monotherapy.
  • Repeated courses or prolonged treatment are often necessary.

GENERAL MEASURES


If cultures show secondary infection, treat with appropriate antibiotics. á

MEDICATION


  • Topicals
    • Topical agents generally have favorable side effect profiles but may be ineffective, especially as monotherapy. Application under occlusion enhances absorption:
      • Vitamin D3 analogs, such as calcipotriol: alone or combined with topical tacrolimus, betamethasone dipropionate, or oral acitretin (8)
      • Topical corticosteroids, with or without occlusion
      • May be combined with an oral antibiotic such as a tetracycline (8)
    • 5-Fluorouracil (8)
    • Tacrolimus ointment, with or without occlusion (8)
    • Anthralin (7)
  • Systemics
    • Systemic medications are generally more effective than topicals, although may be more expensive and carry increased risk of adverse effects.
    • Tumor necrosis factor-╬▒ (TNF-╬▒) inhibitors
      • Adalimumab has shown greatest effectiveness at 40 mg every 1 to 2 weeks (7,8,9,10); may also be safe and effective for pediatric patients (11)
      • Etanercept 20 to 50 mg twice per week (8)
      • Infliximab 5 mg/kg IV at 0, 2, and 6 weeks, then at 8-week intervals (8)
      • Ustekinumab (9)
      • Sometimes combined with oral acitretin, methotrexate, cyclosporine, or prednisone
    • Cyclosporine (4,8)
    • Methotrexate (6): alone or in combination with propylthiouracil
    • Anakinra: alone or in combination with acitretin (1)
    • Acitretin: possible synergistic effect with topical calcipotriol (8)
    • Antibiotics
      • Sulfones, namely dapsone
      • Tetracyclines
    • Colchicine

ADDITIONAL THERAPIES


  • Phototherapy and photochemotherapy have been successful as monotherapies or in conjunction with medications.
  • Targeted narrow band ultraviolet B phototherapy
    • As monotherapy or in conjunction with systemic medications (8)
    • Used successfully with thalidomide to treat a pediatric patient (12)
  • Psoralen ultraviolet A
    • With selective hand bath psoralen (8)
  • Low-level polarized polychromatic noncoherent light (LPPL) plus 0.1% methylprednisolone aceponate cream
    • Used successfully in a pregnant patient (13)

ISSUES FOR REFERRAL


If there is suspicion of psoriatic arthritis, refer to a rheumatologist. á

ONGOING CARE


FOLLOW-UP RECOMMENDATIONS


Long-term management by a dermatologist á

PROGNOSIS


  • Generally persistent, chronically relapsing course
  • May lead to severe disability or complications warranting hospitalization

COMPLICATIONS


  • Association with or progression to PPP or GPP
  • Psoriatic arthritis (possible association)
  • Pain and resultant loss of manual dexterity may have significant psychosocial impact.
  • Fever and systemic inflammatory response syndrome
  • Treatment-related complications, depending on agent used

REFERENCES


11 Lutz áV, Lipsker áD. Acitretin- and tumor necrosis factor inhibitor-resistant acrodermatitis continua of Hallopeau responsive to the interleukin 1 receptor antagonist anakinra. Arch Dermatol.  2012;148(3):297-299.22 Sugiura áK. The genetic background of generalized pustular psoriasis: IL36RN mutations and CARD14 gain-of-function variants. J Dermatol Sci.  2014;74(3):187-192.33 Abbas áO, Itani áS, Ghosn áS, et al. Acrodermatitis continua of Hallopeau is a clinical phenotype of DITRA: evidence that it is a variant of pustular psoriasis. Dermatology.  2013;226(1):28-31.44 Ranugha áPS, Kumari áR, Thappa áDM. Acrodermatitis continua of Hallopeau evolving into generalised pustular psoriasis. Indian J Dermatol.  2013;58(2):161.55 Jo áSJ, Park áJY, Yoon áHS, et al. Case of acrodermatitis continua accompanied by psoriatic arthritis. J Dermatol.  2006;33(11):787-791.66 Okuno áH, Ogura áK, Okuyama áR, et al. Two cases of acrodermatitis continua of Hallopeau associated with generalized arthritis. Acta Dermatovenerol Croat.  2013;21(4):265-267.77 Razera áF, Olm áGS, Bonamigo áRR. Neutrophilic dermatoses: part II. An Bras Dermatol.  2011;86(2):195-211.88 Sehgal áVN, Verma áP, Sharma áS, et al. Acrodermatitis continua of Hallopeau: evolution of treatment options. Int J Dermatol.  2011;50(10):1195-1211.99 Di Costanzo áL, Napolitano áM, Patruno áC, et al. Acrodermatitis continua of Hallopeau (ACH): two cases successfully treated with adalimumab. J Dermatolog Treat.  2014;25(6):489-494.1010 Sopkovich áJA, Anetakis Poulos áG, Wong áHK. Acrodermatitis continua of Hallopeau successfully treated with adalimumab. J Clin Aesthet Dermatol.  2012;5(2):60-62.1111 Dini áV, Barbanera áS, Romanelli áM. Efficacy of adalimumab for the treatment of refractory paediatric acrodermatitis continua of hallopeau. Acta Derm Venereol.  2013;93(5):588-589.1212 Kiszewski áAE, De Villa áD, Scheibel áI, et al. An infant with acrodermatitis continua of Hallopeau: successful treatment with thalidomide and UVB therapy. Pediatr Dermatol.  2009;26(1):105-106.1313 Choi áM, Na áSY, Cho áS, et al. Low level light could work on skin inflammatory disease: a case report on refractory acrodermatitis continua. J Korean Med Sci.  2011;26(3):454-456.

CODES


ICD10


L40.2 Acrodermatitis continua á

ICD9


696.1 Other psoriasis á

SNOMED


  • Acrodermatitis continua (disorder)
  • Acrodermatitis continua of Hallopeau
  • Localized acrodermatitis continua of Hallopeau (disorder)

CLINICAL PEARLS


  • Rare variant of pustular psoriasis that preferentially affects the fingers and toes, often leading to significant pain and loss of function
  • Classically refractory to treatment, although case reports show that a variety of agents may have limited efficacy. Adalimumab may be the most promising option.
Copyright © 2016 - 2017
Doctor123.org | Disclaimer